Messenger Ribonucleic Acid (mRNA) Synthesis and Manufacturing Market Report 2026

The messenger ribonucleic acid (mrna) synthesis and manufacturing market size has grown rapidly in recent years. It will grow from $5.14 billion in 2025 to $5.79 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to limited availability of mRNA synthesis platforms, early-stage research in mRNA therapeutics, reliance on small-scale laboratory production, nascent regulatory frameworks, high cost of purification and formulation services.

The messenger ribonucleic acid (mrna) synthesis and manufacturing market size is expected to see rapid growth in the next few years. It will grow to $9.22 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to technological advancements in automated mRNA synthesis, expansion of commercial-scale mRNA manufacturing facilities, rising investment in vaccine and therapeutic pipelines, increasing demand for self-amplifying mRNA and novel formulations, growth in preclinical and clinical research collaborations. Major trends in the forecast period include increasing adoption of gmp-compliant mrna synthesis, rising demand for large-scale mrna production, expansion of mrna therapeutics and vaccine pipelines, enhanced focus on purification capping and tailing services, growing integration of mrna-lnp formulations and stability testing.

The rising prevalence of infectious diseases is expected to drive growth in the messenger ribonucleic acid (mRNA) synthesis and manufacturing market in the coming years. Infectious diseases are disorders caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, including illnesses like malaria that can spread directly or indirectly. The increasing prevalence of these diseases is largely due to rapid urbanization, which results in higher population density and closer human contact, facilitating the spread of infections. mRNA synthesis and manufacturing play a critical role in combating infectious diseases by enabling the rapid development and scalable production of targeted vaccines and therapeutics that elicit specific immune responses. For example, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from about 7.5 million in 2022, making tuberculosis the leading infectious disease killer. This indicates that the growing prevalence of infectious diseases is fueling growth in the mRNA synthesis and manufacturing market.

Key companies in the mRNA synthesis and manufacturing market are focusing on innovative products, such as co-transcriptional capping platforms, to accelerate preclinical research and reduce regulatory hurdles. A co-transcriptional capping platform is a proprietary method that efficiently attaches a protective cap to mRNA molecules during synthesis, improving stability, translation efficiency, and control over immunogenicity. For instance, in May 2025, GenScript, a U.S.-based life sciences research tools company, launched its GMP-like mRNA manufacturing service. This scalable, regulatory-aware service produces high-purity, functional mRNA for investigational new drug (IND)-enabling preclinical studies, including toxicology, biodistribution, and pharmacokinetic or pharmacodynamic assessments. Built in cleanroom-compliant, ISO 7-classified environments, the service incorporates patented co-transcriptional capping technology and delivers customized mRNA in as little as seven weeks. This solution bridges the gap between research-grade and full GMP manufacturing, enabling early-stage biotechnology and pharmaceutical companies to conduct regulatory-aligned studies efficiently and cost-effectively.

In June 2024, BioNTech, a Germany-based biotechnology company, acquired CureVac for an undisclosed sum. Through this acquisition, BioNTech aims to combine CureVac’s proprietary mRNA technology, RNA printer platform, and clinical pipeline with its own global infrastructure and development capabilities to strengthen its position in infectious diseases and oncology. CureVac is a Germany-based biopharmaceutical company specializing in mRNA synthesis and manufacturing.

Major companies operating in the messenger ribonucleic acid (mrna) synthesis and manufacturing market are Thermo Fisher Scientific Inc., Evonik Industries AG, Moderna Inc., BioNTech SE, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, Catalent Inc., WuXi Biologics (Cayman) Inc., Samsung Biologics Co Ltd., GenScript Biotech Corporation, Arcturus Therapeutics Holdings Inc., New England Biolabs Inc., CureVac N.V., Abzena plc, Creative Biolabs Inc., Aldevron LLC, eTheRNA immunotherapies NV, Bio-Synthesis Inc., TriLink BioTechnologies LLC.

North America was the largest region in the messenger ribonucleic acid (mRNA) synthesis and manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) synthesis and manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the messenger ribonucleic acid (mrna) synthesis and manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the mRNA synthesis and manufacturing market by increasing costs of imported raw materials, enzymes, nucleotides, and LNP formulation components. Commercial-scale and GMP-compliant mRNA production segments are particularly impacted, with regions such as North America and Europe experiencing higher import duties. This has led to elevated production costs and supply chain delays. On the positive side, tariffs have encouraged local sourcing, investment in domestic production infrastructure, and innovation in alternative reagents and materials.

The messenger ribonucleic acid (mrna) synthesis and manufacturing market research report is one of a series of new reports that provides messenger ribonucleic acid (mrna) synthesis and manufacturing market statistics, including messenger ribonucleic acid (mrna) synthesis and manufacturing industry global market size, regional shares, competitors with a messenger ribonucleic acid (mrna) synthesis and manufacturing market share, detailed messenger ribonucleic acid (mrna) synthesis and manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) synthesis and manufacturing industry. This messenger ribonucleic acid (mrna) synthesis and manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Messenger ribonucleic acid (mRNA) synthesis and manufacturing is a biotechnological process involving the design, production, and purification of mRNA molecules at scale for use in therapeutics and vaccines. This process includes transcribing synthetic DNA templates into mRNA through enzymatic reactions, followed by purification, formulation, and quality control to ensure the mRNA is stable, effective, and safe for clinical or commercial applications.

The primary types of mRNA synthesis and manufacturing are mRNA drug synthesis and mRNA vaccine synthesis. mRNA drug synthesis encompasses the laboratory and industrial procedures for designing, synthesizing, and producing mRNA sequences intended for therapeutic use. These processes are carried out at multiple scales, including preclinical, clinical, and commercial stages. The applications cover various therapeutic areas such as infectious diseases, oncology, and others, and support uses including vaccine production, therapeutic development, drug discovery, and more.

The messenger ribonucleic acid (mRNA) synthesis and manufacturing market consists of sales of synthetic deoxyribonucleic acid (DNA) templates, in vitro transcription kits, enzymes, nucleotides, purification systems, and formulation reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.